The global Biopharmaceuticals Contract Manufacturing market accounted for USD 17.14 billion in 2023 and is expected to reach USD 30.15 billion by 2034 with a CAGR of 5.27% during the forecast period 2024-2034. Increasing demand for biopharmaceuticals, increased outsourcing by pharmaceutical companies, technological advancements, a growing pipeline of biopharmaceutical products, and strategic partnerships and collaborations will all fuel market expansion.
Advances in bioprocessing technologies, such as single-use systems, continuous manufacturing, and process automation, have increased the efficiency, scalability, and quality of pharmaceutical manufacturing. Contract manufacturers frequently invest in cutting-edge technology to improve their manufacturing skills and provide clients with access to cutting-edge production facilities and knowledge. For instance, in February 2023, the Lonza Group announced a $1.2 billion expansion of its mammalian cell production facility in Visp, Switzerland.
By source, the mammalian cells segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the high demand for complex biologics requiring mammalian cell-based expression systems, such as monoclonal antibodies and recombinant proteins, which are widely used in the treatment of various diseases, driving the need for specialized manufacturing expertise and infrastructure. For instance, in October 2023, Catalent entered into a strategic agreement with a big pharmaceutical company to produce a new gene treatment. Additionally, the non-mammalian segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of alternative expression systems, such as microbial and yeast-based platforms, which offer advantages such as cost-effectiveness, scalability, and rapid production timelines, especially for certain types of biopharmaceuticals like vaccines and biosimilars.
By service, the fill & finish operations segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the high demand for specialized services in the final stages of biopharmaceutical manufacturing, including formulation, filling, and packaging, which are crucial for ensuring product stability, sterility, and compliance with regulatory requirements. For instance, in January 2024, Thermo Fisher Scientific acquired Biovian, a contract development and manufacturing organization (CDMO) that specialized in viral vector production. Additionally, the process development segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on optimizing bioprocesses for improved yield, efficiency, and product quality, driving demand for contract manufacturing services specializing in process development to accelerate drug development timelines and enhance manufacturing capabilities.
By product, the biologics segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the growing demand for biologics as innovative treatment options for various diseases, driving the need for contract manufacturing services specialized in biopharmaceutical production, including cell line development, upstream and downstream processing, and formulation, to meet market demand and ensure product quality and compliance. For instance, in November 2023, Fujifilm Diosynth Biotechnologies announced a $2 billion commitment to expand its manufacturing capacity in the United States and Europe. Additionally, the biosimilar segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing patent expirations of biologic drugs, driving demand for biosimilar development and manufacturing to provide cost-effective alternatives, leading to greater adoption of contract manufacturing services specialized in biosimilar production to capitalize on market opportunities and meet regulatory requirements.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the increasing prevalence of cancer worldwide and the growing pipeline of oncology biologics, driving demand for contract manufacturing services specialized in oncology drug development and production to meet the rising demand for innovative cancer therapies and improve patient outcomes. For instance, in September 2023, AGC Biologics partnered with a biopharmaceutical business to develop and produce a breakthrough cancer medication. Additionally, the gene therapy and cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in gene editing technologies and increasing investment in cell-based therapies, driving demand for contract manufacturing services specialized in gene therapy and cell therapy manufacturing to meet the growing pipeline of innovative treatments and address unmet medical needs in areas such as rare genetic disorders, cancer, and regenerative medicine.
By end-user, the biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the increased outsourcing of manufacturing activities by biopharmaceutical companies to focus on core competencies such as research and development, driving demand for contract manufacturing services specialized in biopharmaceutical production to meet the growing demand for innovative therapies and improve operational efficiency. For instance, in February 2024, Sartorius Stedim Biotech introduced a new single-use bioprocessing technology platform for efficient and flexible manufacturing. Additionally, the contract research organizations (CROs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of outsourcing trends in pharmaceutical research and development, driving demand for contract research organizations specializing in biopharmaceutical development services to provide cost-effective solutions, accelerate drug development timelines, and enhance innovation in the industry.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established biopharmaceutical industry, favorable regulatory environment, strong infrastructure for research and development, and high investment in healthcare driving demand for contract manufacturing services and contributing to the region's dominance in the global biopharmaceuticals contract manufacturing market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing by pharmaceutical companies, growing investments in healthcare infrastructure, rising demand for cost-effective manufacturing solutions, and expanding biopharmaceutical market opportunities, particularly in emerging economies such as India and China. For instance, in December 2023, Novasep announced the increase of their chromatography media manufacturing capacity to accommodate increasing demand.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Advances in bioprocessing technologies, such as single-use systems, continuous manufacturing, and process automation, have increased the efficiency, scalability, and quality of pharmaceutical manufacturing. Contract manufacturers frequently invest in cutting-edge technology to improve their manufacturing skills and provide clients with access to cutting-edge production facilities and knowledge. For instance, in February 2023, the Lonza Group announced a $1.2 billion expansion of its mammalian cell production facility in Visp, Switzerland.
By source, the mammalian cells segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the high demand for complex biologics requiring mammalian cell-based expression systems, such as monoclonal antibodies and recombinant proteins, which are widely used in the treatment of various diseases, driving the need for specialized manufacturing expertise and infrastructure. For instance, in October 2023, Catalent entered into a strategic agreement with a big pharmaceutical company to produce a new gene treatment. Additionally, the non-mammalian segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of alternative expression systems, such as microbial and yeast-based platforms, which offer advantages such as cost-effectiveness, scalability, and rapid production timelines, especially for certain types of biopharmaceuticals like vaccines and biosimilars.
By service, the fill & finish operations segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the high demand for specialized services in the final stages of biopharmaceutical manufacturing, including formulation, filling, and packaging, which are crucial for ensuring product stability, sterility, and compliance with regulatory requirements. For instance, in January 2024, Thermo Fisher Scientific acquired Biovian, a contract development and manufacturing organization (CDMO) that specialized in viral vector production. Additionally, the process development segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on optimizing bioprocesses for improved yield, efficiency, and product quality, driving demand for contract manufacturing services specializing in process development to accelerate drug development timelines and enhance manufacturing capabilities.
By product, the biologics segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the growing demand for biologics as innovative treatment options for various diseases, driving the need for contract manufacturing services specialized in biopharmaceutical production, including cell line development, upstream and downstream processing, and formulation, to meet market demand and ensure product quality and compliance. For instance, in November 2023, Fujifilm Diosynth Biotechnologies announced a $2 billion commitment to expand its manufacturing capacity in the United States and Europe. Additionally, the biosimilar segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing patent expirations of biologic drugs, driving demand for biosimilar development and manufacturing to provide cost-effective alternatives, leading to greater adoption of contract manufacturing services specialized in biosimilar production to capitalize on market opportunities and meet regulatory requirements.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the increasing prevalence of cancer worldwide and the growing pipeline of oncology biologics, driving demand for contract manufacturing services specialized in oncology drug development and production to meet the rising demand for innovative cancer therapies and improve patient outcomes. For instance, in September 2023, AGC Biologics partnered with a biopharmaceutical business to develop and produce a breakthrough cancer medication. Additionally, the gene therapy and cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in gene editing technologies and increasing investment in cell-based therapies, driving demand for contract manufacturing services specialized in gene therapy and cell therapy manufacturing to meet the growing pipeline of innovative treatments and address unmet medical needs in areas such as rare genetic disorders, cancer, and regenerative medicine.
By end-user, the biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals contract manufacturing market in 2023 owing to the increased outsourcing of manufacturing activities by biopharmaceutical companies to focus on core competencies such as research and development, driving demand for contract manufacturing services specialized in biopharmaceutical production to meet the growing demand for innovative therapies and improve operational efficiency. For instance, in February 2024, Sartorius Stedim Biotech introduced a new single-use bioprocessing technology platform for efficient and flexible manufacturing. Additionally, the contract research organizations (CROs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of outsourcing trends in pharmaceutical research and development, driving demand for contract research organizations specializing in biopharmaceutical development services to provide cost-effective solutions, accelerate drug development timelines, and enhance innovation in the industry.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established biopharmaceutical industry, favorable regulatory environment, strong infrastructure for research and development, and high investment in healthcare driving demand for contract manufacturing services and contributing to the region's dominance in the global biopharmaceuticals contract manufacturing market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing by pharmaceutical companies, growing investments in healthcare infrastructure, rising demand for cost-effective manufacturing solutions, and expanding biopharmaceutical market opportunities, particularly in emerging economies such as India and China. For instance, in December 2023, Novasep announced the increase of their chromatography media manufacturing capacity to accommodate increasing demand.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Source, Product, Service, Therapeutic Area, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Biopharmaceuticals Contract Manufacturing Market Report 2023 - 2034
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Source 2023 - 2034 (Revenue USD Bn)
- Mammalian
- Non-mammalian
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Process Development
- Fill & Finish Operations
- Analytical & QC studies
- Packaging
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Service 2023 - 2034 (Revenue USD Bn)
- Biologics
- Monoclonal antibodies (MABs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Oncology
- Autoimmune Diseases
- Metabolic Diseases
- Cardiovascular Diseases
- Neurology
- Infectious Diseases
- Others
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Biopharmaceutical Companies
- Pharmaceutical Companies
- Research Organizations
- Others
Biopharmaceuticals Contract Manufacturing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis
8. Biopharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis
9. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis
10. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
11. Biopharmaceuticals Contract Manufacturing Market: Distribution Channel Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Biopharmaceuticals Contract Manufacturing Market
14. Europe Global Biopharmaceuticals Contract Manufacturing Market
15. Asia Pacific Global Biopharmaceuticals Contract Manufacturing Market
16. Latin America Global Biopharmaceuticals Contract Manufacturing Market
17. MEA Global Biopharmaceuticals Contract Manufacturing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Lonza Group
- Catalent Inc.
- Samsung Biologics
- WuXi Biologics
- Boehringer Ingelheim
- Thermo Fisher Scientific Inc.
- AbbVie Contract Manufacturing
- Fujifilm Diosynth Biotechnologies
- Patheon (now part of Thermo Fisher Scientific)
- AGC Biologics
- Cytovance Biologics
- Sartorius Stedim Biotech
- Charles River Laboratories
- Novasep
- Rentschler Biopharma.
